Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
Myriad Genetics received approval from Japan's Ministry of Health, Labour and Welfare to expand its MyChoice Test to prostate cancer patients as a companion diagnostic for Lynparza, broadening access to genomic testing in Japan and enabling more precise treatment decisions for prostate, breast, and ovarian cancers.